Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Turkish Journal of Gastroenterology

Volumn 22, Issue 6, 2011, Pages 582-586

  Seven, Gülseren ^a   Çinar, Kubilay ^a   Yakut, Mustafa ^a   Idilman, Ramazan ^a   Özden, Ali ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

First line therapy; Helicobacter pylori; Levofloxacin

Indexed keywords

AMOXICILLIN; LEVOFLOXACIN; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PROTON PUMP INHIBITORS;

EID: 84856276885     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2011.0255     Document Type: Article

References (35)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter Study Group. Eur J Gastroenterol Hepatol 1997; 9: 1-2. (Pubitemid 27047348)
2. Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter Study Group. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81. (Pubitemid 46854190)
3. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25. (Pubitemid 47206706)
4. Fock KM, Katelaris P, Sugano K, et al.; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.
5. Gispert JP, Boixeda D, Aller R, et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection, efficacy of three triple therapies and role of eradication in the prevention of recurrent hemorrhage. Med Clin 1999; 112: 161-5. (Pubitemid 29100463)
6. Gispert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole. A meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
7. Calvet X, Ducons J, Bujanda L, et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005; 100: 1696-701. (Pubitemid 41648420)
8. Boixeda D, Martin de Argila C, Bermejo F, et al. Seven day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. Factors that influence Helicobacter pylori eradication success. Rev Esp Enferm Dig 2003; 95: 202-5.
9. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole-levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
10. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006; 11: 39-45.
11. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006; 101: 1985-90. (Pubitemid 44337620)
12. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized study. Gut 2010; 59: 1465-70.
13. Buzás GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16: 3865-70.
14. Paoluzi OA, Visconti E, Andrei F, et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 2010; 44: 261-6.
15. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci 2000; 45: 265-71. (Pubitemid 30133884)
16. Malfertheiner P, Megraud F, Giguere M, Riviere M. Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori (Abstract). Gastroenterology 2010; 138 (Suppl 1): S-33.
17. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
18. O'Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22: 1123-7.
19. Raymond J, Lamarque D, Kalach N, et al. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010; 15: 21-7.
20. Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41: 747-50. (Pubitemid 47267760)
21. Tuzun Y, Bayan K, Yilmaz S, et al. The prevalence of primary and secondary Helicobacter pylori resistance to clarithromycin and probable contributing cofactors: data from southeastern Anatolia. Hepatogastroenterology 2008; 55: 289-93. (Pubitemid 351462211)
22. Kadayifci A, Buyukhatipoglu H, Savas MC, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 28: 1960-6. (Pubitemid 46043508)
23. Seven G, Özden A. Increased resistance of Helicobacter pylori against clarithromycin. Does it gain stability? Akademik Gastroenteroloji 2010; 2: 67-9.
24. Özden A, Soykan I, Çetinkaya H, et al. Kisa süreli üçlü tedavi kombinasyonlarinin Helicobacter pylori eradikasyonundaki etkisi (Abstract). Turk J Gastroenterol 1998; 9 (Suppl 1): A161.
25. Soykan I, Çetinkaya H, Özden A. Uzun ve kisa süreli lansoprazol-klaritromisin-amoksisilin kombinasyonunun Helicobacter pylori eradikasyonuna etkisi (Abstract). Turk J Gastroenterol 1997; 8 (Suppl 1): A208.
26. Zou J, Yang ZX, Qin ZM. Laboratory and clinical study of levofloxacin against Helicobacter pylori. Zhonghua Yi Xue Za Zhi 2003; 83: 1778-81.
27. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49: 1039-40. (Pubitemid 34692903)
28. Chang WL, Sheu BS, Cheng HC, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009; 24: 1230-5.
29. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 26: 495-500. (Pubitemid 47063147)
30. Gispert JP, Morena F. Systematic review and metaanalysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44. (Pubitemid 43381164)
31. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs. levofloxacin in firstline triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
32. Ercin C, Uygun A, Toros A, et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol 2010; 21: 12-6.
33. Di Caro S, Franceschi S, Mariani A, et al. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009; 41: 480-5.
34. Castro-Fernandez M, Lamas E, Perez-Pastor A, et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as a first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 2009; 6: 395-402.
35. Chen LW, Chien RN, Chang JJ, et al. Comparison of oncedaily levofloxacin- containing triple therapy and twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomized study. Int J Clin Pract 2010; 64: 1530-4.